Literature DB >> 35342474

Increased prevalence of cardiovascular risk factors in newly diagnosed type 2 diabetes patients - a retrospective study.

G Roman1, G Teodorescu2.   

Abstract

Context: Identification of CV risk factors from T2DM diagnosis allows optimization of treatment to prevent CV complications and death. Objective: The primary objective of the study was to describe the CV risk factors in patients with T2DM at the time of diagnosis and/or therapeutic specific measures taken. Design: This was a non-interventional, multicenter, retrospective chart review of newly diagnosed patients with T2DM in 49 study centers in Romania. Subjects and
Methods: Adults with a diagnosis of T2DM between January - December 2014. Statistical analysis used appropriate descriptive methods.
Results: 1218 patients were included, mean age (SD) at diagnosis was 59.16 (10.87) years. Half of the patients (54%) presented obesity and 47.7% of patients had arterial hypertension. Overall, 76.2% of subjects had LDL-cholesterol ≥ 100 mg/dL, and 59.1% had triglycerides ≥ 150 mg/dL. The mean glycemia was 198.8 mg/dL (78.3) and 50.2% of patients had HbA1c ≥7%. Sedentary lifestyle in 73.8% of the cases, and 91.3% unhealthy eating habits reported. In addition to diet, 82.2% of patients received anti-diabetes treatment, 62.6% lipid-lowering, and 66.6% anti-hypertensive medication.
Conclusion: This retrospective study showed a high prevalence of CV risk factors and/or established CV disease at the time of T2DM diagnosis in Romania. ©2021 Acta Endocrinologica (Buc).

Entities:  

Keywords:  HbA1c; Type 2 Diabetes; arterial hypertension; cardiovascular risk factors; dyslipidemia; insulin resistance; obesity

Year:  2021        PMID: 35342474      PMCID: PMC8919485          DOI: 10.4183/aeb.2021.331

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  24 in total

1.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

Review 2.  CHOICE OF THE ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CLINICAL PRACTICE. INITIAL RESULTS FROM A NON-INTERVENTIONAL MULTICENTER STUDY IN ROMANIA (REALITY).

Authors:  C Serafinceanu; R Timar; D Catrinoiu; A Zaharia
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

4.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

Review 5.  Multiple risk factors for cardiovascular disease and diabetes mellitus.

Authors:  Sidney C Smith
Journal:  Am J Med       Date:  2007-03       Impact factor: 4.965

6.  Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).

Authors:  Elizabeth L M Barr; Paul Z Zimmet; Timothy A Welborn; Damien Jolley; Dianna J Magliano; David W Dunstan; Adrian J Cameron; Terry Dwyer; Hugh R Taylor; Andrew M Tonkin; Tien Y Wong; John McNeil; Jonathan E Shaw
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

7.  Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study.

Authors:  S Popa; M Moţa; A Popa; E Moţa; C Serafinceanu; C Guja; D Catrinoiu; N Hâncu; R Lichiardopol; C Bala; A Popa; G Roman; G Radulian; R Timar; B Mihai
Journal:  J Endocrinol Invest       Date:  2016-04-28       Impact factor: 4.256

8.  Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.

Authors:  Christos Kalofoutis; Christina Piperi; Anastasios Kalofoutis; Fred Harris; David Phoenix; Jaipaul Singh
Journal:  Exp Clin Cardiol       Date:  2007

Review 9.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

10.  2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  John B Buse; Deborah J Wexler; Apostolos Tsapas; Peter Rossing; Geltrude Mingrone; Chantal Mathieu; David A D'Alessio; Melanie J Davies
Journal:  Diabetes Care       Date:  2019-12-19       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.